Patient preferences and satisfaction with antiretroviral therapy;Preferencias y satisfacción de los pacientes con el tratamiento antirretroviral

Enfermedades Infecciosas y Microbiologia Clinica Monografias

Volumn 4, Issue 1, 2005, Pages 38-42

  Ibarra Barrueta, Olatz ^a  

^a HOSPITAL DE GALDAKAO   (Spain)

Author keywords

Adherence; Antiretroviral therapy; HAART; Preference; Satisfaction

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; NUCLEOSIDE ANALOG;

ANXIETY; ARTICLE; CONFUSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; LIPODYSTROPHY; NAUSEA; PATIENT COMPLIANCE; PATIENT SATISFACTION; SIDE EFFECT; VISUAL DISORDER;

EID: 34648830933     PISSN: 16963539     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbility and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-60.
2. th Interscience Conference of Antimicrobial Agents and Chemotherapy; 2000; Toronto. Abstract 699.
3. th Int. ADDS Conference; 2000; Durban. Abstract TuOrB417.
4. Paterson DL, Swindells S, Mohr J, Brester M, Michelle RN, Vergis EN, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
5. Escobar I, Knobel H, Polo R, Ortega L, Martín-Conde M, Casado JL, et al. Recomendaciones GESIDA/SEFH/PNS para mejorar la adherencia al tratamiento antirretroviral en el año 2004. Farm Hosp. En prensa.
6. Videla S, Cobo E. Evaluación de la eficacia en VIH-1. Marco clínico en la investigación de VIH-1. En: Cobo E, Videla S, Clotet B, editores. Investigación clínica y estadística. Badalona: Fundació de Lluita contra el Sida; 2003.
7. Casado JL, Knobel H, Ruiz I, González J, on behalf of the GEEMA Study Group. Change in adherence level and outcome of HIV Infection: the importance of the consistency of adherence to antiretroviral therapy. 42nd ICAAC Abstracts; 2002, September 27-30; San Diego. Abstract H-1707.
8. Iribarren JA, Labarga P, Rubio R, Berenguer J, Miró JM, Antela A, et al. Recomendaciones de GESIDA/ PNS respecto al tratamiento antirretroviral en pacientes adultos infectados por el VIH-1 (octubre 2004). Enferm Infecc Microbiol Clin. 2004;22:564-642.
9. Ribera E, Aguirrebengoa K, Miralles C, Antela A, Rivero A, Arribas JR. Simplificación del tratamiento antirretroviral. Enferm Infecc Microbiol Clin. 2002;20:48-57.
10. Knobel H, Guelar A. Estrategias para optimizar la adherencia al tratamiento antirretroviral. Intervenciones en la pauta terapéutica. Enferm Infecc Microbiol Clin. 2004;22:106-12.
11. Daar ES, Cohen C, Remien R, Sherer R, Smith K. Improving adherence to antirretroviral therapy. AIDS Read. 2003;13:81-90.
12. Fumaz CR, Muñoz J, Ferrer MJ, Tuldrá A, Clotet B. Valoración de los cambios en la adhesión al tratamiento y la calidad de vida tras la simplificación de la terapia antirretroviral. AIDS Cyber J. 2003;6:138-42.
13. Ibarra O, Alonso M, Bachiller MP, Balzola B, Bilbao J, Ercilla M, et al. La evolución del tratamiento antirretroviral en hospitales del Pais Vasco. En VII Congreso Nacional sobre el Sida; 2003, Mayo 7-9; Bilbao. Abstract EC2p2. p. 178.
14. Gordillo V, Del Amo J, Soriano V, González-Lahoz J. Sociodemographic and psychologic variables influencing adherence to antiretroviral therapy. AIDS. 1999;13:1763-9.
15. Duran S, Spire B, Raffi F, Walter V, Bouhour D, Journot V, et al. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials. 2001;2:38-45.
16. Griffith S. A review of the factors associated with patient compliance and the taking of prescribed medicines. Br J Gen Pract. 1990;40:114-6.
17. Trotta MP, Ammassari A, Melzi S, Zaccarelli M, Ladisa N, Sighinolfi L, et al. Treatment-related factors and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr. 2002;31:S128-31.
18. Stone VE, Hogan JW, Schuman P, Rompalo AM, Howard AA, Korkontzelou C, et al. Antiretroviral regimen complexity, self-reported adherence, and HIV patients' understanding of their regimens: survey of women in the HER study. J Acquir Immune Defic Syndr. 2001;28:124-31.
19. Altice FL, Mostashari F, Friedland GH. Trust and acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;28:47-58.
20. Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral- naive HIV-1 infected adults. AIDS. 2001;15:1369-77.
21. nd IAS Conference on HIV Pathogenesis and Treatment; 2003, July 13-16. Paris. Abstract 757. p. S395.
22. Ammassari A, Murri R, Pezzotti P, Trotta MP, Ravasio L, De Longis P, et al. Self-reported symptoms and medications side effects influence adherence to highly active antirretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr. 2001;28:445-9.
23. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23: 1296-310.
24. Grimes RM, Lal L, Lewis ST. Frequency and medical history items, drug interactions, and lifestyle characteristics that may interfere with antiretroviral medications. HIV Clin Trials. 2002;3:161-7.
25. Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SA. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr. 2000;23:386-95.
26. Nieuwkerk PT, Sprangers MAG, Burger DM, Hoetelmans RW, Hugen PW, Danner SA, et al. Limited patient adherence to highly active antiretroviral therapy for HFV-1 infection in an observational cohort study. Arch Intern Med. 2001;161:1962-8.
27. Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAuliffe TL. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol. 2000;19:124-33.
28. Moatti JP, Carrieri MP, Spire B, Gastaut JA, Cassuto JP, Moreau J, et al. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. AIDS. 2000;14: 151-5.
29. Murri R, Ammassari A, Gallicano K, De Luca A, Cingolani A, Jacobson D, et al. Patient-reported nonadherence to HAART is related to protease inhibitor levels. J Acquir Immune Defic Syndr. 2000;24:123-8.
30. Heath KV, Singer J, O'Shaughnessy MV, Montaner JSG, Hogg RS. Intentional nonadherence due to adverse symptoms associated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31:211-7.
31. Holzemer WL, Corless IB, Nokes KM, Turner JG, Brown MA, Powell-Cope GM, et al. Predictors of self-reported adherence in persons living with HIV disease. AIDS Patient Care STD. 1999;13:185-97.
32. Duran S, Savès M, Spire B, Cailleton V, Sobel A, Carrieri P, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS. 2001;15:2441-4.
33. Hawkins T. Impact of once- and twice-daily dosing regimens on adherence and overall safety. AIDS Read. 2004;14:320-2, 324, 329-31, 334-6.
34. Piscitelli SC, Flexner C. Scheduling Medications in HIV Disease. Medscape [citado 27 Jul 2000]. Disponible en: http://www.medscape.com/viewprogram/673? src=search
35. Eron J, Yetzer E, Ruane P, Becker S, Sawyerr GA, Fisher RL, et al. Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection. AIDS. 2000;14:671-81.
36. Clumeck N, Goebel F, Rozenbaum W, Gerstoft J, Staszewski S, Montaner J, et al. Simplification with abacavir- based triple nucleoside therapy versus continued protease inhibitor- based highly active antiretroviral therapy in HIV-1 infected patients with undetectable plasma HIV-1 RNA. AIDS. 2001;15:1517-26.
37. Muñoz-Moreno JA, Fumaz CR, Negredo E, Moltó J, Gel S, Puig J, et al. Impact of a once-daily antirretroviral regimens on quality of fife and adherence to treatment of HIV infected patients with viral load suppression. XV International AIDS Conference; 2004; Bangkok. Abstract TuPeB4602.
38. nd IAS Conference on HIV Pathogenesis and Treatment; 2003, July 13-16; Paris. Abstract 763. p. S397.
39. Knobel H, Viciana P, Cervero M, Santos J, Colmenero MA, Montejo M, et al. The impact to switch to a simpler HAART for adherence and on patient related risk factors for non-adherence. XV International AIDS Conference; 2004; Bangkok. Abstract WePeB5773.
40. Moya J, Casado JL, Aranzabal L, Marín A, Moreno A, Antela A, et al. Simplificación a terapia "una vez al día" (QD) en pacientes con infección por VIH-1 que reciben terapia dos veces al día (BID): eficacia, tolerancia, farmacocinética y cambios en la adherencia. VIII Congreso Nacional sobre el Sida; 2004; Madrid. Abstract P1-66.40.
41. Boening AJ, Yuan Y, Smith D, Iloeje U. Cost savings associated with low pill burden (LPB) and high adherence (HADH) in protease inhibitor treated HIV-infected Patients. 43rd ICAAC; 2003; September. Abstract A-1365.
42. Biglino A, Degioanni M, Valle M, Crivelli P, Brusa MT, Mastinu A, et al. Lack of adherence to antiretrovirals caused by pill burden; efficacy and safety of simplification to a triple-nucleoside regimen (Trizivir). XV International AIDS Conference; 2004; Bangkok. Abstract TuPeB4572.
43. Arribas JR, Iribarren JA, Knobel H, Ribera E, Rubio R, Viciana P, et al. Adherence, treatment satisfaction and effectiveness of once-daily (QD) vs. twice- daily (BID) antirretroviral therapy (AT), in a large prospective observational cohort (CUVA Study). XV International AIDS Conference; 2004; Bangkok. Abstract WePeB5780.
44. Bertholon DR, Rossert H, Korsia S. The patient's perspective on life with antiretroviral treatment: results of an 887- person survey. AIDS Read. 1999;9:462-9.
45. Knobel H, Rubio R, Miró J, et al. Adherence to antiretroviral therapy: the patient perspective (Estudio PACTA). 7th European Conference on Clinical Aspects and Treatment of HIV-Infection; Lisbon. Oct 23-27, 1999.
46. Woodcock A, Bradley C. Validation of the treatment satisfaction questionnaire (HIVTSQ). Qual Life Res. 2001;10:517-31.
47. Jordan J, Cahn P, Vibhagool A. Patient satisfaction with treatment is associated with adherence and treatment continuation: results from CNA3014 study. 42nd ICAAC; 2002, September 27-30; San Diego. Abstract O-1011.
48. Moyle G. The Assessing Patients' Preferred Treatments (APPT-1) study. Int J Std AIDS. 2003;14 Suppl 1: 34-6.
49. Stone VE, Jordan J, Tolson J, Miller R, Pilon T. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy. J Acquir Immune Defic Syndr. 2004;36:808-16.